Time New York: Sun 09 Dec 14:47 pm  |  Save 15% on H&R Block Online

  
caticonslite_bm_alt

AbbVie’s Orilissa Gets Canadian Nod to Treat Endometriosis

Zacks

AbbVie ABBV along with its partner Neurocrine Biosciences, Inc. NBIX announced that Health Canada has approved Orilissa (elagolix), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, for the treatment of moderate to severe pain associated with endometriosis. Orilissa was approved in the United States in July 2018 for the same indication.

The approval was supported by positive data from two replicate phase III studies, which evaluated Orilissa for the given indication in women. The detailed data from the analysis showed that treatment with Orilissa resulted in statistically significant reductions in menstrual and non-menstrual pelvic pain associated with endometriosis compared with placebo. Orilissa is expected to be launched in Canada early November.

Endometriosis affects an estimated one in 10 women of reproductive age and is associated with pain symptoms. The pain associated with it is currently managed with oral contraceptives, progestins, danazol, NSAIDS, opioids and GnRH agonists. Many medicines are not specifically indicated for treating endometriosis. With Orilissa approved to treat pain associated with endometriosis, it can address a market with significant unmet need to bring in more revenues for AbbVie.

Shares of AbbVie have lost 2.2% year to date versus the industry’s increase of 7.1%.


We remind investors that Orilissa is also being studied for the treatment of uterine fibroids in women. In August, the company announced positive top-line data from phase III extension study on Orilissa for the same. Outcomes data from the phase III ELARIS UF-EXTEND (M12-816) study demonstrated that Elagolix (300 mg twice daily) in combination with low-dose add-back therapy reduced heavy menstrual bleeding in 87.9% of women with uterine fibroids at month 12 of the regime.

Zacks Rank & Stocks to Consider

AbbVie currently has a Zacks Rank #3 (Hold).

Bristol-Myers Squibb Co. BMY and Roche AG RHHBY are better-ranked stocks from the same space, sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Bristol-Myers’ earnings per share estimates have increased from $3.59 to $3.63 for 2018 and from $3.83 to $3.92 for 2019 over the past 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 6.39%. Share price of the company has increased 2.0% year to date.

Roche’s earnings per share estimates have increased from $2.14 to $2.24 for 2018 and from $2.15 to $2.28 for 2019 over the past 60 days. Share price of the company has increased 1.8% year to date.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research
<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.